Hopefully, the identification of novel interactions between canonical pathways deregulated in T-ALL for which clinically relevant inhibitors are available (such as Cn-NFAT and PI3K/AKT/mTOR pathways) could lead to to a more effective therapy of T-ALL patients still facing a poor prognosis. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.